Editorial Archive
The Raven Brief: Systems-Based Insights for Western New York Patients
An editorial archive of clinical insights, white papers, and investigative health analyses on complex endocrine and metabolic function. Built for the thoughtful reader seeking an advanced understanding of their individual physiology in WNY.
The Lean Mass Problem: What the GLP-1 Conversation Is Missing
GLP-1 medications produce real, measurable weight loss — and the cardiovascular data is genuine. What the prescribing conversation has not yet caught up with is what the manufacturers' own registration trials document clearly: a substantial fraction of the weight lost is lean mass, not fat.
Lean mass governs resting metabolic rate, insulin sensitivity, functional capacity, and survival. In the patient populations these drugs are now recommended for first, its preservation is especially important. This brief examines what the trial data actually shows, why it matters clinically, and what a more complete approach to metabolic care should include.
Clinical white paper · 9 pages · 15 min readWhat This Brief Covers
- What the STEP 1, SURMOUNT-1, and SEMALEAN trials actually show about lean mass loss
- Why lean mass is not cosmetic — and what its loss means metabolically
- The bone density question and the cardiovascular paradox
- What comprehensive metabolic care should include alongside or instead of GLP-1 therapy
- A clinical decision framework for two distinct patient scenarios
The Metabolic Safety Gap: Why Standard Lifestyle Advice Fails the Hypothyroid Patient
Eat less, move more. It is the advice given to every patient with weight concerns — including those with hypothyroidism and Hashimoto’s thyroiditis. For a significant proportion of those patients, it does not work. Not because they are non-compliant, but because their biology does not respond to caloric restriction and high-intensity exercise the way a euthyroid body does.
This brief examines the three biological mechanisms through which standard lifestyle advice actively deepens thyroid dysfunction — at the level of the enzymes, the hormonal feedback loops, and the mitochondrial response. It then addresses why identifying the patient’s specific hormonal recruitment pattern is the clinical work that must precede any protocol.
Clinical white paper · 9 pages · 15 min readWhat This Brief Covers
- The Deiodinase Brake — how caloric restriction triggers a starvation signal that suppresses T3 production and why selenium from food sources matters
- The Cortisol-Thyroid Feedback Loop — how high-intensity exercise drives Reverse T3 accumulation and deepens metabolic suppression
- The Cell Danger Response — why the mitochondria of a hypothyroid patient remain in defense mode and what that means for exercise recovery
- The sarcopenic risk — why the standard model preferentially depletes lean mass and compounds the dysfunction it was meant to correct
- Why sixteen possible hormonal recruitment patterns exist — and why the HPT-primary protocol in this brief does not apply to every patient who presents with thyroid symptoms
The Lean Mass Problem: What the GLP-1 Conversation Is Missing
The Metabolic Safety Gap: Why Standard Lifestyle Advice Fails the Hypothyroid Patient
Redefining ‘Normal’: A Guide to Advanced Lab Interpretation
Receive New Issues of The Raven Brief
New issues publish quarterly. Each brief is a standalone clinical analysis — no marketing, no supplement recommendations, no wellness clichés. Just careful thinking about complex physiology.
Quarterly Publication · No Spam
Subscribe to The Raven Brief You will be directed to a secure editorial subscription form in a new window.